Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
HIV Med
    April 2024
  1. CALZA L, Giglia M, Colangeli V, Bon I, et al
    Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain.
    HIV Med. 2024 Apr 3. doi: 10.1111/hiv.13644.
    >> Share

    March 2024
  2. SAWRY S, Ayalew K, Maimela G, Briggs-Hagen M, et al
    Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    HIV Med. 2024 Mar 22. doi: 10.1111/hiv.13638.
    >> Share

  3. JACOBS TG, Okemo D, Ssebagereka A, Mwehonge K, et al
    Availability and stock-outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda.
    HIV Med. 2024 Mar 18. doi: 10.1111/hiv.13635.
    >> Share

  4. DOU Y, Lu R, Su L, Lan K, et al
    Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
    HIV Med. 2024 Mar 17. doi: 10.1111/hiv.13632.
    >> Share

  5. FURSA O, Bannister W, Neesgaard B, Podlekareva D, et al
    SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort.
    HIV Med. 2024 Mar 3. doi: 10.1111/hiv.13620.
    >> Share

    January 2024
  6. ROSSOTTI R, D'Amico F, Bana NB, Nava A, et al
    Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
    HIV Med. 2024 Jan 23. doi: 10.1111/hiv.13615.
    >> Share

  7. ARORA AK, Vicente S, Engler K, Lessard D, et al
    Impact of social determinants of health on time to antiretroviral therapy initiation and HIV viral undetectability for migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite B/F/TAF: 'The ASAP study'.
    HIV Med. 2024 Jan 11. doi: 10.1111/hiv.13608.
    >> Share

  8. KOH MCY, Ngiam JN, Yong J, Tambyah PA, et al
    The role of an artificial intelligence model in antiretroviral therapy counselling and advice for people living with HIV.
    HIV Med. 2024 Jan 2. doi: 10.1111/hiv.13604.
    >> Share

    December 2023
  9. ESSER S, Brunetta J, Inciarte A, Levy I, et al
    Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts.
    HIV Med. 2023 Dec 26. doi: 10.1111/hiv.13593.
    >> Share

  10. RANZANI A, Castelli F, Di Biagio A, d'Arminio Monforte A, et al
    Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects.
    HIV Med. 2023 Dec 17. doi: 10.1111/hiv.13600.
    >> Share

  11. MCGEE DM, Cotter AG
    HIV and fracture: Risk, assessment and intervention.
    HIV Med. 2023 Dec 12. doi: 10.1111/hiv.13596.
    >> Share

    October 2023
  12. WATERS L, Hassan Wada Y, Barber TJ
    International AIDS society conference 2023 summary.
    HIV Med. 2023 Oct 23. doi: 10.1111/hiv.13563.
    >> Share

  13. AMBROSIONI J, Levi L, Alagaratnam J, Van Bremen K, et al
    Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
    HIV Med. 2023 Oct 18. doi: 10.1111/hiv.13542.
    >> Share

  14. GACIC N, Tulloch K, Money D, Tkachuk S, et al
    Daily ritonavir-boosted darunavir for viral suppression in pregnancy (DRV-P).
    HIV Med. 2023 Oct 10. doi: 10.1111/hiv.13546.
    >> Share

  15. BEGRE L, Boyd A, Salazar-Vizcaya L, Suter-Riniker F, et al
    Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.
    HIV Med. 2023 Oct 10. doi: 10.1111/hiv.13561.
    >> Share

  16. FRANGE P, Veber F, Burgard M, Blanche S, et al
    Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
    HIV Med. 2023 Oct 8. doi: 10.1111/hiv.13562.
    >> Share

    September 2023
  17. LUI GC, Wong GL, Yang HC, Sheng WH, et al
    Current practice and recommendations for management of hepatitis B virus in people living with HIV in Asia.
    HIV Med. 2023 Sep 21. doi: 10.1111/hiv.13545.
    >> Share

    August 2023
  18. SHENGIR M, Lebouche B, Elgretli W, Saeed S, et al
    Switch to a raltegravir-based antiretroviral regimen in people with HIV and non-alcoholic fatty liver disease: A randomized controlled trial.
    HIV Med. 2023 Aug 28. doi: 10.1111/hiv.13531.
    >> Share

    July 2023
  19. CHAN TY, Marta M, Rackstraw S
    Relapse of neurosymptomatic cerebrospinal fluid HIV RNA escape.
    HIV Med. 2023 Jul 24. doi: 10.1111/hiv.13527.
    >> Share

    June 2023
  20. ZINO L, Tack CJ, Richel O, Burger DM, et al
    GLP-1 agonists for people living with HIV and obesity, is there a potential?
    HIV Med. 2023 Jun 20. doi: 10.1111/hiv.13521.
    >> Share

  21. DEKOVEN S, Naccarato M, Brumme CJ, Tan DHS, et al
    Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
    HIV Med. 2023 Jun 14. doi: 10.1111/hiv.13520.
    >> Share

    May 2023
  22. ROMO ML, Esber AL, Owuoth J, Maswai J, et al
    Impact of weight gain with dolutegravir on antiretroviral adherence and viral suppression in four African countries.
    HIV Med. 2023 May 25. doi: 10.1111/hiv.13501.
    >> Share

  23. PALMIER E, De Miguel R, Montejano R, Busca C, et al
    Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study.
    HIV Med. 2023 May 16. doi: 10.1111/hiv.13500.
    >> Share

    April 2023
  24. SURIAL B, Wandeler G
    Tenofovir alafenamide and weight: What do we still need to know to inform clinical decisions?
    HIV Med. 2023 Apr 24. doi: 10.1111/hiv.13497.
    >> Share

  25. FITZGERALD N, Coltart H, Dominguez L, Flanagan K, et al
    PrEP for women in Europe: a systematic literature review.
    HIV Med. 2023 Apr 23. doi: 10.1111/hiv.13458.
    >> Share

  26. NASREDDINE R, Florence E, Yombi JC, Henrard S, et al
    Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
    HIV Med. 2023 Apr 10. doi: 10.1111/hiv.13493.
    >> Share

  27. HOCQUELOUX L, Menard A, Arvieux C, Joly V, et al
    Weight gain following the single substitution of tenofovir disoproxil fumarate by tenofovir alafenamide in HIV-infected people from the French Dat'AIDS cohort: A propensity score-matched analysis.
    HIV Med. 2023 Apr 4. doi: 10.1111/hiv.13488.
    >> Share

    March 2023
  28. DUNN K, Bushen J, Luo D, Cai J, et al
    Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
    HIV Med. 2023;24:279-289.
    >> Share

  29. AVIHINGSANON A, Chetchotisakd P, Kiertiburanakul S, Ratanasuwan W, et al
    Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials.
    HIV Med. 2023;24:290-300.
    >> Share

    February 2023
  30. MOUNZER K, Brunet L, Fusco JS, McNicholl IR, et al
    Immune response to ART initiation in advanced HIV infection.
    HIV Med. 2023 Feb 15. doi: 10.1111/hiv.13467.
    >> Share

    November 2022
  31. MAGGI P, Ricci ED, Muccini C, Galli L, et al
    Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV-specific risk factors; the Archi-Prevaleat project.
    HIV Med. 2022 Nov 30. doi: 10.1111/hiv.13448.
    >> Share

  32. BENDALA-ESTRADA AD, Diaz-Almiron M, Busca C, Mican R, et al
    Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
    HIV Med. 2022 Nov 16. doi: 10.1111/hiv.13432.
    >> Share

    October 2022
  33. PAPADOPOULOS A, Thomas K, Protopapas K, Antonyak S, et al
    HIV treatment strategies across Central, Eastern and Southeastern Europe: New times, old problems.
    HIV Med. 2022 Oct 4. doi: 10.1111/hiv.13416.
    >> Share


  34. IN BRIEF: BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022.
    HIV Med. 2022;23 Suppl 3:3-14.
    >> Share

    September 2022
  35. HIKASA S, Shimabukuro S, Hideta K, Higasa S, et al
    Comparison between the impact of tenofovir alafenamide and that of abacavir on rapid kidney function decline: A retrospective observational study.
    HIV Med. 2022 Sep 20. doi: 10.1111/hiv.13408.
    >> Share

  36. FULLER T, Fragoso da Silveira Gouvea MI, Benamor Teixeira ML, Ferreira Medeiros A, et al
    Real-world experience with weight gain among pregnant women living with HIV who are using integrase inhibitors.
    HIV Med. 2022 Sep 5. doi: 10.1111/hiv.13388.
    >> Share

    August 2022
  37. AKSAK-WAS BJ, Kowalska JD, Zabek P, Serwin K, et al
    Immune restoration affects 10-year survival in people living with HIV/AIDS.
    HIV Med. 2022 Aug 25. doi: 10.1111/hiv.13391.
    >> Share

  38. SHAFRAN SD, Hughes CA
    Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
    HIV Med. 2022 Aug 16. doi: 10.1111/hiv.13376.
    >> Share

  39. PERELLO R, Losada A, Chen J, Supervia A, et al
    Amphetamine-related intoxications in people living with HIV: An observational study in an emergency department in Barcelona (Spain) from 2018 to 2020.
    HIV Med. 2022 Aug 9. doi: 10.1111/hiv.13365.
    >> Share

  40. NASREDDINE R, Yombi JC, Darcis G, Florence E, et al
    Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
    HIV Med. 2022 Aug 8. doi: 10.1111/hiv.13373.
    >> Share

    June 2022
  41. BROWN JA, Nsakala BL, Mokhele K, Rakuoane I, et al
    Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
    HIV Med. 2022 Jun 22. doi: 10.1111/hiv.13352.
    >> Share

    May 2022
  42. GIZAW A, King WC, Hinerman AS, Chung RT, et al
    A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (HBV)-HIV co-infection with high prevalence of tenofovir-based antiretroviral therapy use.
    HIV Med. 2022 May 16. doi: 10.1111/hiv.13322.
    >> Share

  43. MAGGIOLO F, Rizzardini G, Molina JM, Pulido F, et al
    Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people >/=65 years of age.
    HIV Med. 2022 May 8. doi: 10.1111/hiv.13319.
    >> Share

    March 2022
  44. RYOM L, De Miguel R, Cotter AG, Podlekareva D, et al
    Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
    HIV Med. 2022 Mar 25. doi: 10.1111/hiv.13268.
    >> Share

  45. GEDELA K, Rajus N, Luis H, Fridayantara WD, et al
    Antiretroviral drug switches to zidovudine-based regimens and loss to follow-up during the first COVID-19 lockdown in Bali, Indonesia.
    HIV Med. 2022 Mar 21. doi: 10.1111/hiv.13298.
    >> Share

  46. DING H, Xu J, Liu J, Wang Q, et al
    Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study.
    HIV Med. 2022;23 Suppl 1:64-71.
    >> Share

  47. BAI R, Lv S, Hua W, Su B, et al
    Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.
    HIV Med. 2022;23 Suppl 1:72-83.
    >> Share

  48. ALVAREZ H, Rava M, Martinez C, Portilla J, et al
    Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
    HIV Med. 2022 Mar 1. doi: 10.1111/hiv.13265.
    >> Share

    February 2022
  49. ROSSETTI B, Fabbiani M, Di Carlo D, Incardona F, et al
    Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe.
    HIV Med. 2022 Feb 24. doi: 10.1111/hiv.13262.
    >> Share

  50. CERVO A, Sebastiani G, Milic J, Krahn T, et al
    "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV".
    HIV Med. 2022 Feb 24. doi: 10.1111/hiv.13274.
    >> Share

  51. LEE MJ, Nori A, Fidler S, Kulasegaram R, et al
    Response to 'The use of tenofovir in patients with COVID-19'.
    HIV Med. 2022 Feb 22. doi: 10.1111/hiv.13278.
    >> Share

  52. RASI V, Peters H, Sconza R, Francis K, et al
    Trends in antiretroviral use in pregnancy in the UK and Ireland, 2008-2018.
    HIV Med. 2022 Feb 18. doi: 10.1111/hiv.13243.
    >> Share

    January 2022
  53. ADLER Z, Fitzpatrick C, Broadwell N, Churchill D, et al
    Chemsex and antiretroviral prescribing in an HIV cohort in Brighton, UK.
    HIV Med. 2022 Jan 20. doi: 10.1111/hiv.13239.
    >> Share

  54. KOW CS, Ramachandram DS, Hasan SS
    The use of tenofovir in patients with COVID-19.
    HIV Med. 2022 Jan 12. doi: 10.1111/hiv.13228.
    >> Share

    December 2021
  55. CAMPBELL L, Ibrahim F, Barbini B, Samarawickrama A, et al
    Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
    HIV Med. 2021 Dec 5. doi: 10.1111/hiv.13215.
    >> Share

  56. LAKATOS B, Kowalska J, Antoniak S, Gokengin D, et al
    Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19).
    HIV Med. 2021 Dec 3. doi: 10.1111/hiv.13214.
    >> Share

  57. REEVES I, Cromarty B, Deayton J, Dhairyawan R, et al
    British HIV Association guidelines for the management of HIV-2 2021.
    HIV Med. 2021;22 Suppl 4:1-29.
    >> Share

    November 2021
  58. O'NEIL PJ, Stafford KA, Ryscavage PA
    Assessing risk factors for hypertension in young adults with perinatally acquired HIV infection: A case-control study.
    HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13199.
    >> Share

    October 2021
  59. CASTILLO-MANCILLA JR, Musinguzi N, Asiimwe S, Siedner MJ, et al
    High residual inflammation despite HIV viral suppression: Lessons learned from real-time adherence monitoring among people with HIV in Africa.
    HIV Med. 2021 Oct 26. doi: 10.1111/hiv.13200.
    >> Share

  60. BURNS JE, Stirrup O, Waters L, Dunn D, et al
    No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naive adults.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13186.
    >> Share

  61. TUFA TB, Fuchs A, Orth HM, Lubke N, et al
    Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia.
    HIV Med. 2021 Oct 7. doi: 10.1111/hiv.13176.
    >> Share

    September 2021
  62. WONG IKJ, Grulich AE, Poynten IM, Polizzotto MN, et al
    Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012.
    HIV Med. 2021 Sep 28. doi: 10.1111/hiv.13179.
    >> Share

  63. VENKATESH KK, Edmonds A, Westreich D, Dionne-Odom J, et al
    Associations between HIV, antiretroviral therapy and preterm birth in the US Women's Interagency HIV Study, 1995-2018: a prospective cohort.
    HIV Med. 2021 Sep 12. doi: 10.1111/hiv.13171.
    >> Share

    July 2021
  64. FABBIANI M, Rossetti B, Ciccullo A, Oreni L, et al
    Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
    HIV Med. 2021 Jul 27. doi: 10.1111/hiv.13146.
    >> Share

  65. SHARMA I
    Interrogating the impact of combination antiretroviral therapies on HIV-associated neurocognitive disorders.
    HIV Med. 2021 Jul 21. doi: 10.1111/hiv.13142.
    >> Share

  66. TORRES B, Guardo AC, Squarcia M, Diaz A, et al
    Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial.
    HIV Med. 2021 Jul 20. doi: 10.1111/hiv.13114.
    >> Share

  67. LEI JJH, Pereira B, Moyle G, Boffito M, et al
    The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV.
    HIV Med. 2021 Jul 13. doi: 10.1111/hiv.13137.
    >> Share

    June 2021
  68. ZHABOKRITSKY A, Szadkowski L, Burchell AN, Cooper C, et al
    Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC).
    HIV Med. 2021 Jun 1. doi: 10.1111/hiv.13125.
    >> Share

    May 2021
  69. MMASA KN, Powis K, Sun S, Makhema J, et al
    Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
    HIV Med. 2021 May 18. doi: 10.1111/hiv.13120.
    >> Share

    April 2021
  70. KOVARI H, Surial B, Tarr PE, Cavassini M, et al
    Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
    HIV Med. 2021 Apr 20. doi: 10.1111/hiv.13106.
    >> Share

  71. EZEAMAMA AE, Zalwango SK, Sikorskii A, Tuke R, et al
    In utero and peripartum antiretroviral exposure as predictor of cognition in 6- to 10-year-old HIV-exposed Ugandan children - a prospective cohort study.
    HIV Med. 2021 Apr 16. doi: 10.1111/hiv.13094.
    >> Share

    March 2021
  72. KANDA N, Okamoto K, Okumura H, Mieno M, et al
    Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
    HIV Med. 2021 Mar 15. doi: 10.1111/hiv.13061.
    >> Share

    February 2021
  73. JESPERSEN NA, Axelsen F, Dollerup J, Norgaard M, et al
    The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era.
    HIV Med. 2021 Feb 28. doi: 10.1111/hiv.13077.
    >> Share

  74. PUNEKAR YS, Parks D, Joshi M, Kaur S, et al
    Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
    HIV Med. 2021 Feb 2. doi: 10.1111/hiv.13050.
    >> Share

    January 2021
  75. ARMENIA D, Bouba Y, Gagliardini R, Fabeni L, et al
    Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice.
    HIV Med. 2021 Jan 21. doi: 10.1111/hiv.13062.
    >> Share

  76. XU X, Lin H, Chen X, Zhu B, et al
    Differences in hypertension and prehypertension among people living with and without HIV in China: role of HIV infection and antiretroviral therapy.
    HIV Med. 2021 Jan 9. doi: 10.1111/hiv.13040.
    >> Share

  77. LEEME TB, Mine M, Lechiile K, Mulenga F, et al
    Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana.
    HIV Med. 2021;22:1-10.
    >> Share

    December 2020
  78. HOFFMANN C, Casado JL, Harter G, Vizcarra P, et al
    Immune deficiency is a risk factor for severe COVID-19 in people living with HIV.
    HIV Med. 2020 Dec 27. doi: 10.1111/hiv.13037.
    >> Share

  79. FIGUEROA MI, Camiro-Zuniga A, Belaunzaran-Zamudio PF, Sierra Madero J, et al
    The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naive patients with HIV-infection.
    HIV Med. 2020 Dec 17. doi: 10.1111/hiv.13008.
    >> Share

  80. ZHAO Y, Han MJ, Gan XM, Ma Y, et al
    Characteristics and viral suppression among people living with HIV from the National Free Antiretroviral Therapy Programme, 2019.
    HIV Med. 2020;21:701-707.
    >> Share

    November 2020
  81. HSU R, Brunet L, Fusco J, Beyer A, et al
    Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score.
    HIV Med. 2020 Nov 28. doi: 10.1111/hiv.13019.
    >> Share

  82. CHOUDHURY B, Brown J, Ransy DG, Brophy J, et al
    Endothelial activation is associated with intestinal epithelial injury, systemic inflammation and treatment regimen in children living with vertically acquired HIV-1 infection.
    HIV Med. 2020 Nov 5. doi: 10.1111/hiv.13012.
    >> Share

  83. TO KW, Lee SS
    A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections.
    HIV Med. 2020 Nov 3. doi: 10.1111/hiv.12989.
    >> Share

    October 2020
  84. FERNANDEZ I, de Lazzari E, Inciarte A, Diaz-Brito V, et al
    Network meta-analysis of post-exposure prophylaxis randomized clinical trials.
    HIV Med. 2020 Oct 27. doi: 10.1111/hiv.12964.
    >> Share

  85. GAZZOLA L, Tagliaferri G, De Bona A, Mondatore D, et al
    Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?
    HIV Med. 2020 Oct 21. doi: 10.1111/hiv.12984.
    >> Share

  86. QUAH SP, McIntyre M, Wood A, Mc Mullan K, et al
    Once-daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post-exposure prophylaxis following sexual exposure.
    HIV Med. 2020 Oct 16. doi: 10.1111/hiv.12938.
    >> Share

  87. SCHUETTFORT G, Boekenkamp L, Cabello A, Cotter AG, et al
    Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors.
    HIV Med. 2020 Oct 13. doi: 10.1111/hiv.12962.
    >> Share

  88. BALAYAN T, Begovac J, Skrzat-Klapaczynska A, Aho I, et al
    Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group.
    HIV Med. 2020 Oct 5. doi: 10.1111/hiv.12960.
    >> Share

  89. IBRAHIM F, Campbell L, Bailey AC, Stockwell S, et al
    Estimated glomerular filtration rate slopes on tenofovir alafenamide.
    HIV Med. 2020;21:607-612.
    >> Share

  90. DRAVID A, Betha TP, Sharma AK, Gawali R, et al
    Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhi
    HIV Med. 2020;21:578-587.
    >> Share

  91. BLOCH M, John M, Smith D, Rasmussen TA, et al
    Managing HIV-associated inflammation and ageing in the era of modern ART.
    HIV Med. 2020;21 Suppl 3:2-16.
    >> Share

    September 2020
  92. IBRAHIM F, Samarawickrama A, Hamzah L, Vincent R, et al
    Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
    HIV Med. 2020 Sep 27. doi: 10.1111/hiv.12961.
    >> Share

  93. BORGHETTI A, Ciccullo A, Lombardi F, Baldin G, et al
    Transmitted drug resistance to NRTIs and risk of virological failure in naive patients treated with integrase inhibitors.
    HIV Med. 2020 Sep 23. doi: 10.1111/hiv.12956.
    >> Share

  94. ADAMS JL, Murray M, Patel N, Sawkin MT, et al
    Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.
    HIV Med. 2020 Sep 23. doi: 10.1111/hiv.12959.
    >> Share

  95. RYOM L, Cotter A, De Miguel R, Beguelin C, et al
    2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
    HIV Med. 2020 Sep 3. doi: 10.1111/hiv.12878.
    >> Share

  96. GIROMETTI N, Lander F, McOwan A, Nwokolo N, et al
    Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort.
    HIV Med. 2020 Sep 1. doi: 10.1111/hiv.12900.
    >> Share

    July 2020
  97. OKOLI C, Schwenk A, Radford M, Myland M, et al
    Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.
    HIV Med. 2020 Jul 15. doi: 10.1111/hiv.12879.
    >> Share

    June 2020
  98. MWASAKIFWA GE, Amin J, White CP, Center JR, et al
    Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LI
    HIV Med. 2020 Jun 23. doi: 10.1111/hiv.12882.
    >> Share

  99. GANTNER P, Allavena C, Duvivier C, Cabie A, et al
    Post-exposure prophylaxis completion and condom use in the context of potential sexual exposure to HIV.
    HIV Med. 2020 Jun 17. doi: 10.1111/hiv.12880.
    >> Share

  100. SCHRADER SY, Zeder AJ, Hilge R, Bogner JR, et al
    Medium-grade proteinuria is a risk factor for incident markers of chronic kidney disease.
    HIV Med. 2020 Jun 17. doi: 10.1111/hiv.12881.
    >> Share

  101. WATERS L, Rockstroh JK
    Antiretroviral HIV drugs in COVID-19 research: promises and risks. An opinion piece.
    HIV Med. 2020 Jun 16. doi: 10.1111/hiv.12913.
    >> Share

    March 2020
  102. STELLBRINK HJ, Lazzarin A, Woolley I, Llibre JM, et al
    The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
    HIV Med. 2020;21 Suppl 1:3-16.
    >> Share

    February 2020
  103. SCHWARZE-ZANDER C, Piduhn H, Boesecke C, Schlabe S, et al
    Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
    HIV Med. 2020 Feb 17. doi: 10.1111/hiv.12840.
    >> Share

    January 2020
  104. STIRRUP OT, Asboe D, Pozniak A, Sabin CA, et al
    Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
    HIV Med. 2020 Jan 11. doi: 10.1111/hiv.12829.
    >> Share

    December 2019
  105. NOE S, Jonsson-Oldenbuettel C, Jaeger H
    Not all is perfect with Tenofovir alafenamide.
    HIV Med. 2019 Dec 29. doi: 10.1111/hiv.12832.
    >> Share

    November 2019
  106. HAMZAH L, Williams D, Bailey AC, Jones R, et al
    Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
    HIV Med. 2019 Nov 3. doi: 10.1111/hiv.12819.
    >> Share

    October 2019
  107. SERRAO A, Santoro C, Foa R, Chistolini A, et al
    Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients.
    HIV Med. 2019 Oct 16. doi: 10.1111/hiv.12803.
    >> Share

    August 2019
  108. WHITLOCK G, Carbonell M, Blackwell S, Nwokolo N, et al
    Rapid initiation of antiretroviral therapy in those with newly diagnosed HIV infection in London, UK.
    HIV Med. 2019 Aug 19. doi: 10.1111/hiv.12780.
    >> Share

    July 2019
  109. CROXFORD S, Miller RF, Post FA, Harding R, et al
    Cause of death among HIV patients in London in 2016.
    HIV Med. 2019 Jul 5. doi: 10.1111/hiv.12761.
    >> Share

    June 2019
  110. SIWAK E, Horban A, Witak-Jedra M, Cielniak I, et al
    Long-term trends in HIV care entry: over 15 years of clinical experience from Poland.
    HIV Med. 2019 Jun 28. doi: 10.1111/hiv.12762.
    >> Share

    April 2019
  111. SILVA BF, Peixoto G, da Luz SR, de Moraes S, et al
    Adverse effects of chronic treatment with the Main subclasses of highly active antiretroviral therapy: a systematic review.
    HIV Med. 2019 Apr 22. doi: 10.1111/hiv.12733.
    >> Share

  112. JIAMSAKUL A, Kiertiburanakul S, Ng OT, Chaiwarith R, et al
    Long-term loss to follow-up in the TREAT Asia HIV Observational Database (TAHOD).
    HIV Med. 2019 Apr 12. doi: 10.1111/hiv.12734.
    >> Share

  113. MORENO S, Perno CF, Mallon PW, Behrens G, et al
    Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?
    HIV Med. 2019;20 Suppl 4:2-12.
    >> Share

    March 2019
  114. TADESSE BT, Foster A, Aklillu E
    Rebuttal: Response to the comments by Buck et al. on our published article: Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study; HIV Medicine (2019), 20, 147-156.
    HIV Med. 2019 Mar 29. doi: 10.1111/hiv.12742.
    >> Share

  115. WILLIAMS D, Reicher I, Mohammed H, Richardson D, et al
    Secondary adrenal insufficiency from steroid use and co-prescribing of cytochrome p450 3A4 inhibitors.
    HIV Med. 2019 Mar 29. doi: 10.1111/hiv.12723.
    >> Share

  116. BOYD MA, Boffito M, Castagna A, Estrada V, et al
    Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.
    HIV Med. 2019;20 Suppl 1:3-11.
    >> Share

    January 2019
  117. JOHNSON SM, Standing JF, Klein N, Irwin AD, et al
    A case for reduced frequency of CD4 count monitoring for children on combination antiretroviral therapy with consistently undetectable HIV viral load.
    HIV Med. 2019 Jan 28. doi: 10.1111/hiv.12706.
    >> Share

    October 2018
  118. WILLIAMS D, Scott J, Richardson D, Kingdon E, et al
    Management of Renal Disease: utility of a joint HIV-renal clinic.
    HIV Med. 2018 Oct 14. doi: 10.1111/hiv.12684.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016